Adimmune: Important resolutions of the Company’s 2022 regular shareholders’ meeting


Close

Provided by: ADIMMUNE CORPORATION

SEQ_NO

1

Date of announcement

06/29/2022

Time of concert

13:35:54

Subject

 Important resolutions of the Company's 2022
regular shareholders' meeting

Date of events

06/29/2022

To which item it meets

paragraph 18

Statement

1.Date of the shareholders meeting:2022/06/29
2.Important resolutions (1)Profit distribution/ deficit
  compensation: Acknowledgment of the 2021 earnings distribution
3.Important resolutions (2)Amendments to the corporate charter: Approved the
amendment to the Articles of Incorporation
4.Important resolutions (3)Business report and financial statements:
Acknowledgment of the 2021 business report and financial statements
5.Important resolutions (4)Elections for board of directors and
  supervisors: The Election of the 21st Directors (including
Independent Directors):
Newly elected directors:
A Chan, Chi Hsien
B Representative of National Development Fund, Executive Yuan: Tseng,
Mei Hsing
C Representative of National Development Fund, Executive Yuan: Wang, Victor
D Management Committee of Yao Hua Glass Co., Ltd.
E Representative of Jing Mao Investment Co., Ltd.: Lin, Chi Heng
F Representative of Chuan Pu Investment Holding Co., Ltd.: Chen, Chien Fu
G Representative of Chuan Pu Investment Holding Co., Ltd.: Lin, Jung Chin
H Liu, Chung Cheng
Newly elected independent directors:
A Hsu, Siao Po
B He, Mei Hsiang
C Hsu, Yung Sheng
6.Important resolutions (5)Any other proposals:
A Approved the amendment to the Rules of Procedure for Shareholders'Meeting
B Approved the amendment to the Acquisition or Disposal of Assets Procedure
C Approved the release of non compete restrictions on newly elected
directors
7.Any other matters that need to be specified:
The newly elected directors (including independent directors) shall serve
for a term of three years, starting from June 29, 2022 to June 28, 2025.

Disclaimer

Adimmune Corporation published this content on 29 June 2022 and is responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 June 2022 05:46:10 UTC.

Publicnow 2022

All news about ADIMMUNE CORPORATION

Sales 2022 2 090 M
70.3 M
70.3 M
Net income 2022 148 M
4.98 M
4.98 M
Net cash 2022 649
21.8 M
21.8 M
P/E ratio 2022 119x
Yield 2022 0.84%
Capitalization 17 395 M
585
585
EV / Sales 2022 8,01x
EV / Sales 2023 4,60x
Nbr of Employees 564
Free-Float 71.6%

Chart ADIMMUNE CORPORATION
Duration:

Period :

Adimmune Corporation Technical Analysis Chart |  MarketScreener

Technical analysis trends ADIMMUNE CORPORATION

Short Term Mid-Term Long Term
Trends Bullish Bearish Bearish

Income Statement Evolution

Sell

Buy

Mean consensus BUY
Number of Analysts 1
Last Close Price 40,50 TWD
average target price 53,00 TWD
Spread / Average Target 30.9%

.

Leave a Comment